Investors

Corporate Profile

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Founded in 1996, the Company is publicly traded on the NASDAQ Global Market under the ticker symbol SBBP.

| (Common Stock)

Stock chart for: SBBP.O. Currently trading at $4.40 with a 52 week high of $6.24 and a 52 week low of $2.00.

Data provided by Nasdaq. Minimum 15 minutes delayed.

Press Releases

Strongbridge Biopharma plc to Present at the H.C. Wainwright 21st Annual Global Investment Conference and the Janney Montgomery Scott Healthcare Conference 2019

09/03/19

DUBLIN, Ireland and TREVOSE, Pa. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc , (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that...

Read More
Strongbridge Biopharma Announces Key Leadership Appointments to Support Next Stage of Growth

08/13/19

~ Richard S. Kollender Appointed to Chief Operating Officer ~ ~ Robert Lutz Promoted to Chief Financial Officer ~ ~ David Gill Appointed to Board of Directors ~ DUBLIN, Ireland and TREVOSE, Pa. , Aug. 13, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc , (Nasdaq: SBBP), a global...

Read More

Investors

Investors

Corporate Profile

Press Releases

Strongbridge Biopharma plc to Present at the H.C. Wainwright 21st Annual Global Investment Conference and the Janney Montgomery Scott Healthcare Conference 2019

Strongbridge Biopharma Announces Key Leadership Appointments to Support Next Stage of Growth

Upcoming Events